NasdaqCM - Nasdaq Real Time Price ? USD Apollomics, Inc. (APLM) Follow Compare 0.0918 -0.0092 (-9.11%) At close: November 22 at 4:00 PM EST 0.0945 +0.00 +(2.94%) After hours: 7:49 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it will affect a 1-for-100 reverse share split (“Reverse Share Split”) of its class A ordinary shares GlobeNewswire ? yesterday APLM -9.11% APLMW Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 Vebreltinib is efficacious in both treatment na?ve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplificationFOSTER CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today a poster presentation at the 2024 European GlobeNewswire ? 2 months ago APLM -9.11% APLMW Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New Yor GlobeNewswire ? 2 months ago APLM -9.11% APLMW Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million in cash and cash equivalents as of June 30, 2024; cash runway into the third quarter of 2025 FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug can GlobeNewswire ? 3 months ago APLM -9.11% APLMW Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusionsFOSTER CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resi GlobeNewswire ? 3 months ago APLM -9.11% APLMW Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the Company management will be presenting at the Canaccord Genuity 44th Annual Growth Conference taking place on August 13-15, 2024 in Boston, MA. Canaccord Genuity 44th Annual Growth Conference Format: Compan GlobeNewswire ? 3 months ago APLM -9.11% APLMW Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company’s request for a 180-day extension to regain compliance with the continued listing requirements GlobeNewswire ? 4 months ago APLM -9.11% APLMW Apollomics Announces Updated Strategic Focus and Leadership Team Changes Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical needFOSTER CITY, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today an updated strategic focus for the clinical development GlobeNewswire ? 4 months ago APLM -9.11% APLMW Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterationsFOSTER CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced a poster presentation and an oral presentation by partner c GlobeNewswire ? 5 months ago APLM -9.11% APLMW Apollomics Announces Presentation at the 2024 BIO International Convention FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. BIO International Convention (June 3-6, 2024) Format: In-personLocation: San Diego, Californ GlobeNewswire ? 5 months ago APLM -9.11% APLMW Apollomics Announces Private Placement Financing and Addition to Board of Directors FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses. The PIPE financi GlobeNewswire ? 6 months ago APLM -9.11% APLMW Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, GlobeNewswire ? 6 months ago APLM -9.11% APLMW Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancerFOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American A GlobeNewswire ? 7 months ago APLM -9.11% APLMW Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif. Copies of the posters will be made available on the Apollomics website following the presentation at ir.a GlobeNewswire ? 7 months ago APLM -9.11% APLMW Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE GlobeNewswire ? 7 months ago APLM -9.11% APLMW Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024 FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics’ management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provi GlobeNewswire ? 7 months ago APLM -9.11% APLMW Apollomics Names Matthew Plunkett as Chief Financial Officer By Karen E. Roman Apollomics, Inc. (Nasdaq: APLM), a biopharmaceutical company that develops medicines for difficult-to-treat cancers, said it appointed Matthew Plunkett, Ph.D., as Chief Financial Officer. Dr. Plunkett has over 25 years of strategic and financial experience within the biopharmaceutical sector, most recently as CFO at Aeovian Pharmaceuticals, the company said. Before Aeovian, he […] Exec Edge ? 8 months ago APLM -9.11% APLMW Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics. “It’s our pleasure to welcome Matt to the Apollomics team. We expect his financial strategy and business development expertise from working with development and commercial stage public GlobeNewswire ? 8 months ago APLM -9.11% APLMW Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET. Investo GlobeNewswire ? 9 months ago APLM -9.11% APLMW Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price RequirementFOSTER CITY, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on January 16, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance wi GlobeNewswire ? 9 months ago APLM -9.11% APLMW Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return APLM S&P 500 YTD -90.49% +25.15% 1-Year -88.55% +31.54% 3-Year -99.07% +29.92%
